Entera Bio (ENTX) EPS (Weighted Average and Diluted) (2021 - 2026)
Entera Bio (ENTX) recorded quarterly EPS (Weighted Average and Diluted) of $0.07 in Q1 2026, little changed on a QoQ basis from $0.07 in Q4 2025, and up 16.67% year-over-year from $0.06 in Q1 2025.
Entera Bio (ENTX) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Entera Bio has disclosed EPS (Weighted Average and Diluted) across 6 years of filings, most recently posting $0.07 for Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) rose 16.67% year-over-year to $0.07 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $0.27 (up 3.85% YoY) and the FY2025 annual result came in at $0.25, changed 0.0% from the prior year.
- EPS (Weighted Average and Diluted) held at $0.07 in Q1 2026, from $0.07 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.13 in Q1 2022 and troughed at $0.05 in Q1 2024.
- A 5-year average of $0.08 and a median of $0.07 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) slumped 38.46% — and 2025, when it advanced 20.0%.
- Tracing ENTX's EPS (Weighted Average and Diluted) over 5 years: stood at $0.1 in 2022, then tumbled by 30.0% to $0.07 in 2023, then slipped by 14.29% to $0.06 in 2024, then grew by 16.67% to $0.07 in 2025, then changed by 0.0% to $0.07 in 2026.
- Business Quant data shows ENTX's EPS (Weighted Average and Diluted) at $0.07 in Q1 2026, $0.07 in Q4 2025, and $0.07 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 0.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -0.61 |
| 10 | Entera Bio | 56.59 Mn | 52.45 Mn | - | 0.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.07 |
| Dec 31, 2025 | 0.07 |
| Sep 30, 2025 | 0.07 |
| Jun 30, 2025 | 0.06 |
| Mar 31, 2025 | 0.06 |
| Dec 31, 2024 | 0.06 |
| Sep 30, 2024 | 0.08 |
| Jun 30, 2024 | 0.06 |
| Mar 31, 2024 | 0.05 |
| Dec 31, 2023 | 0.07 |
| Sep 30, 2023 | 0.08 |
| Jun 30, 2023 | 0.08 |
| Mar 31, 2023 | 0.08 |
| Dec 31, 2022 | 0.10 |
| Sep 30, 2022 | 0.11 |
| Jun 30, 2022 | 0.11 |
| Mar 31, 2022 | 0.13 |
| Dec 31, 2021 | 0.15 |
| Sep 30, 2021 | 0.11 |
| Jun 30, 2021 | 0.10 |